Why I’ve Bought Reckitt Benckiser Group plc’s Spin-Off, Indivior PLC

Reckitt Benckiser Group Plc’s (LON: RB) spin-off Indivior PLC (LON: INDV) looks to be undervalued.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At the end of last year, Reckitt Benckiser (LSE: RB) spun off its pharmaceutical division — previously named RB Pharmaceuticals — into a new company called Indivior (LSE: INDV). Reckitt’s management has been trying to refocus the company’s portfolio over the past year or so, and the Indivior spin-off was part of this plan.

Reckitt has been trying to dispose of Indivior for some time. The pharmaceutical company’s sales have been on the slide after US regulators gave the green light to other manufacturers to produce rival generic versions of its heroin substitute drug, Suboxone.

And Indivior’s declining revenues have impacted Reckitt’s growth. For example, during the third quarter Reckitt’s sales only expended by 2%, although growth would have been 3% excluding Indivior. Reckitt is expecting full-year revenue growth of 4% to 5% now Indivior has been spun off. 

An interesting opportunity 

On its first day of trading, Indivior jumped by 17% as demand for the company’s shares was high. It’s easy to see why. Indivior was spun off in a hurry and Reckitt, it seems, couldn’t be bothered to wait around to get the best price.

Indivior is a global leader in the treatment of opioid dependence, with over two decades of history behind it. The group’s core products, namely the drug Suboxone, are sold in up to 44 countries.

Sales of Suboxone tablets have recently come under attack from generic competitors. However, Indivior has fought back with Suboxone film, the sales of which are holding up relatively well. 

Still, there’s no denying the fact that Indivior is under pressure. Total revenues from the Indivior business are expected to fall by more than 12% this year and profits are likely to fall by 25%, due to lower net revenues but also higher R&D costs.

But here’s the thing, at present levels, Indivior is cheap, really cheap. The company currently trades at an estimated 2014 P/E of 5 and a forward P/E of 9, both of which are significantly below the pharmaceutical sector average P/E of 30. Full-year 2014 earnings per share are expected to be somewhere in the region of 31p per share.

Management has stated that it will payout 40% of earnings as a dividend. So, based on this, at current levels Indivior is set to support a yield of around 7% this year.  

Additionally, the company is highly cash-generative and a gross margin of nearly 80% has been reported for the past five years. 

Room for growth 

Indivior is cheap but the company is cheap for a reason; sales are falling. However, now the company is independent it can focus on growth, and Indivior’s potential market is huge. 

Twelve million people abuse opioids annually in the US and 2.5m of them need treatment for addiction. At present Indivior only treats a quarter of these patients.

What’s more, the company has a pipeline of drugs under development that will hit the market over the next few years. These new treatments include drugs for cocaine overdose and alcohol dependency, as well as treatments for schizophrenia. One new product launch is planned every year from 2016 through to 2020. With over 250 sales reps in the US alone, Indivior already has the infrastructure in place to shift these new products. 

Cheap growth 

So all in all, Indivior is cheap, cash-generative, is set to support a hefty dividend yield and has the foundations in place to grow rapidly from 2016 onwards. I believe the company offers long-term growth and income at an extremely attractive price. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of Indivior. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »